Pharmaceuticals

Esketamine Market Forecast 2026–2030 Highlighting Expansion Across Industries

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Esketamine Market Grow Between 2026 And 2030?

The esketamine market size has seen a rapid increase in recent years. It is anticipated to expand from $1.51 billion in 2025 to $1.67 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The historical growth trajectory can be attributed to several factors including unmet needs in major depressive disorder, the limitations inherent in traditional antidepressants, the successful obtainment of regulatory approvals for nasal esketamine, a heightened awareness surrounding mental health issues, and the broadening reach of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth during the forecast period include the rising incidence of treatment-resistant depression, the increasing need for quickly effective treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key trends for the forecast period involve a greater acceptance for treatment-resistant depression, wider use of nasal spray administration, increased application in urgent psychiatric settings, enhanced monitoring and regulated distribution, and expanding investigations into rapid-onset antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Strong Drivers Are Impacting The Esketamine Market Growth?

The increasing prevalence of treatment-resistant depression (TRD) is projected to boost the growth of the esketamine market in the coming years. TRD refers to a form of depression that fails to improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in TRD is attributed to the limited effectiveness of conventional antidepressants, which often leads to prolonged and recurrent depressive episodes. Esketamine aids TRD by employing a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments in 2023. Hence, the increasing incidence of treatment-resistant depression is fueling the expansion of the esketamine market.

Which Segment Classifications Are Used In The Esketamine Market Segment Analysis?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Influencing Demand In The Esketamine Market?

Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Firms Are Contributing To The Esketamine Market Ecosystem?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Get The Full Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Represents The Largest Share Of The Esketamine Market?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Esketamine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795